CTX0E03 Neural Stem Cells Modulate Inflammation for Psychiatric Disorders

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for psychiatric disorders such as depression and obsessive compulsive disorder are often ineffective, require long-term chronic treatment, and have significant side effects due to their impact on brain neurotransmitters and receptors, with a large population not responding to conventional drug therapy and experiencing delayed therapeutic benefits.

Innovation Solution

The use of the CTX0E03 neural stem cell line, which reduces and modulates pro-inflammatory cytokines, providing a safe and potent allogeneic treatment for psychiatric disorders by inhibiting immune system activation and inflammation, particularly for unipolar and bipolar depression, schizophrenia, obsessive compulsive disorder, and autism.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional anti-depressant drugs are used, then therapeutic benefit is achieved in some patients, but treatment requires long-term chronic administration and produces unwanted side effects

Engineering Contradiction:
Improvetherapeutic efficacyVSAvoidside effects
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses neural stem cells as intermediary agents that mediate therapeutic effects through immunomodulation and neurogenesis rather than direct neurotransmitter modulation. The stem cells act as biological intermediaries that secrete trophic factors and regulate immune responses, providing therapeutic benefit without the direct receptor-based side effects of conventional drugs

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the fundamental therapeutic parameter from chemical neurotransmitter modulation to cellular immunomodulation and neurogenesis. By shifting from pharmacological parameter changes (receptor binding, neurotransmitter levels) to biological parameter changes (immune cell regulation, neuronal growth), the treatment achieves efficacy while avoiding drug-specific side effects

Inventive Principle:
Principle #35Parameter changes

2Reliability

If conventional anti-depressant drugs are used, then some patients experience therapeutic benefit, but a large population does not respond to treatment

Engineering Contradiction:
Improvetherapeutic response rateVSAvoidtreatment applicability
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The neural stem cells possess multi-functional therapeutic mechanisms including immunomodulation, neurogenesis, and neuroprotection. This universality allows the treatment to address multiple pathological pathways simultaneously, making it applicable to diverse patient populations regardless of their specific neurotransmitter profiles or drug response patterns

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Reliability

If chronic anti-depressant treatment is administered, then cell proliferation and granule cell survival increase, but the treatment timeline is extended and tolerability decreases

Engineering Contradiction:
Improveneurogenic effectVSAvoidtreatment latency
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The neural stem cells are administered in advance as a one-time intervention that initiates long-term neurogenic and immunomodulatory processes. The cells perform preliminary therapeutic action by establishing persistent populations of neurogenic cells and sustained immune regulation, eliminating the need for continuous chronic treatment and its associated latency and tolerability issues

Inventive Principle:
Principle #10Preliminary action

Data Source

PatentEP2590660B1Therapeutic use of neural stem cells
Publication Date: 2019.10.23 RENEURON LTD
  • EP2590660B1 patent drawingFigure 1A~1F
  • EP2590660B1 patent drawingFigure 2A(i)~2B(iii)
  • EP2590660B1 patent drawingFigure 3A~3B

AI summary

The present invention provides an isolated cell obtainable from the CTX0E03 neural stem cell line for use in the treatment of a disorder associated with elevated levels of pro-inflammatory cytokines, wherein the disorder is selected from unipolar and bipolar depression, schizophrenia, obsessive compulsive disorder, autism and autistic syndrome disorders.